E literature was performed on 30 May perhaps 2021, employing PubMed, Cochrane Library, MEDLINE, and EMBASE databases. Search terms inusing PubMed, Cochrane Library, MEDLINE, and EMBASE databases. Search terms cluded the following: “oligometastatic esophageal adenocarcinoma”, “oligometastasis“, incorporated the following: “oligometastatic esophageal adenocarcinoma”, “oligometasta”esophageal cancer oligometastasis”, “esophageal Cirazoline Agonist adenocarcinoma oligometastasis”, “olsis”, “esophageal cancer oligometastasis”, “esophageal adenocarcinoma oligometastasis”, igometastatic gastroesophageal adenocarcinoma”, and “oligometastatic esophageal can”oligometastatic gastroesophageal adenocarcinoma”, and “oligometastatic esophageal cancer”. Articles were restricted to these published in English and German. Provided the relative cer”. Articles were limited to these published in English and German. Provided the relative scarcity of obtainable literature, search results’ references were thoroughly reviewed for scarcity of obtainable literature, search results’ references have been thoroughly reviewed for achievable inclusion to ensure the maximal quantity of out there facts was captured. feasible inclusion to ensure the maximal volume of obtainable details was captured. Offered outcomes were manually reviewed thoroughly for relevance and included retroAvailable results were manually reviewed completely for relevance and incorporated retrospective observational research, potential multicenter trials, an Aluminum Hydroxide supplier ongoing potential ranspective observational research, prospective multicenter trials, an ongoing prospective domized trial, along with a systematic review ofof the offered literature.Duplicate benefits and randomized trial, and also a systematic evaluation the available literature. Duplicate results and those unrelated to the subject matter had been eliminated from further critique. Though not a these unrelated for the subject matter had been eliminated from additional evaluation. Although not systematic review, screening and eligibility for inclusion of relevant research followed a systematic review, screening and eligibility for inclusion of relevant research standard PRISMA guidelines (Figure 1). standard PRISMA guidelinesFigure 1. Flow chart of selection strategy for integrated reviewed manuscripts PRISMA Figure 1. Flow chart of selection method for integrated reviewed manuscripts followingfollowing PRISMA recommendations. suggestions.3. DiscussionCancers 2021, 13,3 of3. Discussion 3.1. Diagnostic Approaches Common diagnostic approaches to esophageal carcinoma with suspected oligometastases stick to the traditional workup strategy when staging esophageal cancer. Depth of tumor invasion and nodal involvement would be the ideal predictors of longterm survival and an essential determinant of therapeutic method, generating thorough initial staging critical to optimize patient outcome. Endoscopy and tissue biopsy stay the initial actions, with careful documentation of tumor location, length, extent of circumferential involvement, and presence of associated Barrett’s esophagus of important importance [12]. Additionally, endoscopic ultrasound (EUS) is usually advisable to aid in assessing tumor depth and nodal staging. The diagnostic yield is increased when EUS is combined with fineneedle aspiration (FNA) when evaluating lymph node metastasis [13]. The possible presence of synchronous or metachronous double main malignancies also highlights the importance of definitive pathologic tissue diagnosis, as the existence of a second distinct tumor.
